Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading stem cell company focused on developing and marketing products in wound care, orthopedic and sports medicine markets announced today its financial results for the second quarter of 2014.
Highlights and Recent Developments
•Increased product revenue for the quarter to $13.3 million - a 151% increase over Q2 2013 and a 32% increase over previous quarter.
Help employers find you! Check out all the jobs and post your resume.
